These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mays LE; Wilson JM Mol Ther; 2011 Jan; 19(1):16-27. PubMed ID: 21119617 [TBL] [Abstract][Full Text] [Related]
3. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. Zhang P; Sun B; Osada T; Rodriguiz R; Yang XY; Luo X; Kemper AR; Clay TM; Koeberl DD Hum Gene Ther; 2012 May; 23(5):460-72. PubMed ID: 22260439 [TBL] [Abstract][Full Text] [Related]
4. Emerging role of regulatory T cells in gene transfer. Cao O; Furlan-Freguia C; Arruda VR; Herzog RW Curr Gene Ther; 2007 Oct; 7(5):381-90. PubMed ID: 17979684 [TBL] [Abstract][Full Text] [Related]
5. Immune responses to AAV in clinical trials. Mingozzi F; High KA Curr Gene Ther; 2007 Oct; 7(5):316-24. PubMed ID: 17979678 [TBL] [Abstract][Full Text] [Related]
6. BALB/c mice show impaired hepatic tolerogenic response following AAV gene transfer to the liver. Breous E; Somanathan S; Wilson JM Mol Ther; 2010 Apr; 18(4):766-74. PubMed ID: 20068550 [TBL] [Abstract][Full Text] [Related]
7. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. Zhu J; Huang X; Yang Y J Clin Invest; 2009 Aug; 119(8):2388-98. PubMed ID: 19587448 [TBL] [Abstract][Full Text] [Related]
8. AAV as an immunogen. Vandenberghe LH; Wilson JM Curr Gene Ther; 2007 Oct; 7(5):325-33. PubMed ID: 17979679 [TBL] [Abstract][Full Text] [Related]
9. Immune responses to AAV in clinical trials. Mingozzi F; High KA Curr Gene Ther; 2011 Aug; 11(4):321-30. PubMed ID: 21557723 [TBL] [Abstract][Full Text] [Related]
10. IL12-mediated liver inflammation reduces the formation of AAV transcriptionally active forms but has no effect over preexisting AAV transgene expression. Gil-Fariña I; Di Scala M; Vanrell L; Olagüe C; Vales A; High KA; Prieto J; Mingozzi F; Gonzalez-Aseguinolaza G PLoS One; 2013; 8(7):e67748. PubMed ID: 23844082 [TBL] [Abstract][Full Text] [Related]
11. The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer. Boisgerault F; Mingozzi F Curr Gene Ther; 2015; 15(4):381-94. PubMed ID: 26122097 [TBL] [Abstract][Full Text] [Related]
12. Role of FoxP3 Muñoz-Melero M; Biswas M Hum Gene Ther; 2024 Jul; 35(13-14):439-450. PubMed ID: 38450566 [TBL] [Abstract][Full Text] [Related]
13. The Balance between CD8 Kumar SRP; Hoffman BE; Terhorst C; de Jong YP; Herzog RW Mol Ther; 2017 Apr; 25(4):880-891. PubMed ID: 28284982 [TBL] [Abstract][Full Text] [Related]
14. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Cooper M; Nayak S; Hoffman BE; Terhorst C; Cao O; Herzog RW Hum Gene Ther; 2009 Jul; 20(7):767-76. PubMed ID: 19309290 [TBL] [Abstract][Full Text] [Related]
15. Augmentation of transgene-encoded protein after neonatal injection of adeno-associated virus improves hepatic copy number without immune responses. Tai DS; Hu C; Kim EH; Lipshutz GS Pediatr Res; 2015 Sep; 78(3):239-246. PubMed ID: 26042522 [TBL] [Abstract][Full Text] [Related]
16. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Martino AT; Suzuki M; Markusic DM; Zolotukhin I; Ryals RC; Moghimi B; Ertl HC; Muruve DA; Lee B; Herzog RW Blood; 2011 Jun; 117(24):6459-68. PubMed ID: 21474674 [TBL] [Abstract][Full Text] [Related]
17. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Zaiss AK; Muruve DA Gene Ther; 2008 Jun; 15(11):808-16. PubMed ID: 18385765 [TBL] [Abstract][Full Text] [Related]
18. Can genes transduced by adeno-associated virus vectors elicit or evade an immune response? Wang CH; Liu DW; Tsao YP; Xiao X; Chen SL Arch Virol; 2004 Jan; 149(1):1-15. PubMed ID: 14689272 [TBL] [Abstract][Full Text] [Related]